Shenzhen Epoch Biodesign Technology Co., Ltd. has recently declared the successful closure of a Pre-A funding round, raising tens of millions of yuan. This funding initiative was spearheaded by Huaxi Yuanyou, with additional investment pouring in from Yigao Capital. Xiqiao Capital played a pivotal role as the exclusive financial advisor for this round.

The capital raised will be earmarked primarily for the iterative enhancement of the company's core research and development platform, CatalEditor®. Epoch Biodesign has made significant strides in pushing the boundaries of protein applications. Leveraging its protein AI design and material encapsulation platform, CatalEditor®, the company has, for the first time, surmounted the inherent functional and structural constraints of proteins.

Professor Ge Jun, the visionary founder of Epoch Biodesign, has achieved noteworthy success in the commercialization of enzyme-MOF technology. CatalEditor® stands out as a trailblazer by seamlessly integrating protein and material design within a unified data framework. This innovative approach facilitates cross-scale collaborative optimization, thereby substantially reducing the research and development timeline.